Imcyse

Avenue du Pré-Aily 14
4031 Liège Angleur
BE
Imcyse
Foundation date
10/08/2010
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
- #Diseases of the blood and blood-forming organs - immune disorders
- #Infectious and parasitic diseases
Imcyse develops active targeted immune therapies (ImotopesÔ) that locally inhibit the immune cells involved in the destruction of the diseased organ. The targeted approach and memory effect of the Imcyse technology help to prevent and cure diseases with no current therapeutic alternative, caused by disruptions of the immune system without impairing the patient’s immune defences.
Upcoming events
All events-
1212 '23
BioFIT 2023
Event by: Eurasanté -
0602 '24
Discovery to Innovation in Animal Health - 2024
Event by: Ghent University, Provaxs, Paul Dick & Associates -
0512 '23
The GxP Academy: Sterilisatie Validatie
Event by: Advipro
Latest news
More news-
Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States
Thursday November 30th 2023
Read more
-
Agomab appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer
Wednesday November 29th 2023
Read more
-
Sequana Medical announces positive data from non-randomized cohort in US Phase 1/2a MOJAVE study of DSR® 2.0 for treatment of heart failure
Wednesday November 29th 2023
Read more
Jobs
More jobs-
03/12/23
Limburg
PhD position in the field of neuroimmunology, mouse modelling and induced pluripotent stem cells
Permanent
VIB -
-
01/12/23
Antwerp, Brussels, East Flanders, Hainaut, Liège, Limburg, Luxembourg, Namur, Flemish Brabant, Walloon Brabant, West Flanders
Sales Engineer Belgium
Permanent
Thema Group Belgium
More info?
Ellen Telleir
Communication Coordinator